The Craniomaxillofacial (CMF) Devices Market is highly consolidated, with major players like Stryker, Johnson & Johnson (DePuy Synthes), Zimmer Biomet, and KLS Martin controlling a significant portion of the global market. Stryker currently leads the industry, leveraging a comprehensive portfolio that spans from cranial flap fixation to advanced distraction systems. A key strategic shift in...

While North America remains the dominant force in the Capsule Endoscopy Market—accounting for over 43% of global revenue—the geographical center of growth is shifting. The Asia-Pacific region is documented as the fastest-growing market in 2025, with a projected CAGR of 10.3%. This growth is fueled by massive healthcare infrastructure expansions in China and India, alongside a...

Despite rapid innovation, the Capsule Endoscopy Market faces significant hurdles related to high initial costs and limited reimbursement. In many regions, the total cost of a capsule procedure—including the single-use device and the specialized workstation—remains higher than traditional endoscopy. While hardware still accounts for 55% of market revenue in 2025, there is an...

 According to a new report from Intel Market Research, the global methyl chloride market was valued at USD 1.17 billion in 2024 and is projected to reach USD 1.40 billion by 2032, growing at a CAGR of 2.5% during the forecast period (2025-2032). This steady growth is driven by persistent demand from pharmaceutical, agrochemical, and silicone...

In 2025, B2B marketing content is more than just a tool for awareness — it’s a strategic driver of qualified leads, pipeline acceleration, and closed revenue. Today’s B2B buyers do extensive research before making purchasing decisions, and the content they encounter along that journey can either accelerate their progress or stall it altogether. Content...

The Human Insulin Market is a "heavyweight" industry dominated by Novo Nordisk, Eli Lilly, and Sanofi, who together control nearly 90% of the global market by value in 2025. These giants are increasingly diversifying their portfolios into GLP-1 receptor agonists (like Ozempic and Mounjaro) which, while competing with insulin in early-stage Type 2 diabetes, are also being explored as...

In 2025, Type 2 Diabetes has emerged as the largest therapeutic segment, accounting for approximately 78% of the total insulin market size. While Type 1 patients have a lifelong, absolute requirement for insulin, the global rise in obesity and sedentary lifestyles has led to a massive increase in insulin-dependent Type 2 cases. This demographic shift is driving a high volume of demand for both...